熱門資訊> 正文

Schrödinger获得SGR-1505快速通道状态

2025-06-27 23:17

Schrödinger (NASDAQ:SDGR) said that the U.S. FDA granted Fast Track status to its MALT1 inhibitor, SGR-1505, for treating adults with Waldenström macroglobulinemia who have not responded to at least two previous therapies.
Fast-track designation allows a faster timeline for the development and review of drugs targeted at serious conditions with unmet medical needs.
It enables developers to communicate frequently with the regulator on plans for clinical studies.

More on Schrödinger

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results
Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript
Schrödinger slides after early-stage trial data for cancer therapy
SA analyst upgrades: ZS, EPR, SEDG, SDGR, KEYS

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。